Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic/RTI

This article was originally published in The Gray Sheet

Executive Summary

Revised human allograft exclusive worldwide distribution agreement includes an option for Medtronic Sofamor Danek to purchase up to $10 mil. of Regeneration Technologies stock. The pact, which relates to RTI's specialty tissue allografts and bone paste used in spinal surgery, also calls for an increase in the licensing and transfer fees paid by Medtronic from 30% to "40-50%," RTI says. The restructured agreement reflects "the value of RTI's proprietary technology," including the BioCleanse tissue sterilization process, according to a June 19 RTI release. A next generation version of the BioCleanse process, introduced June 12, sterilizes tissue from single donors in separate chambers, eliminating the need to batch tissue from multiple donors...

You may also be interested in...



Cohesion Sale Drives Shares In September; O-T-C Index Composite Declines

Cohesion Technologies shares spiked 64% on Sept. 30, the day the firm announced its acquisition by Angiotech Pharmaceuticals. The issue closed September at $3.86, an 81% gain for the month overall

Big Pharma BD Execs Tell Start-Ups: Don’t Be Afraid To Ask Us For Help

Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.

Transformation Into Viatris Not Seen As The Solution Mylan Needs

Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.

UsernamePublicRestriction

Register

MT016773

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel